Randomized, placebo-controlled trial of nonpegylated and pegylated forms of recombinant human alpha interferon 2a for suppression of dengue virus viremia in rhesus monkeys.

@article{Ajariyakhajorn2005RandomizedPT,
  title={Randomized, placebo-controlled trial of nonpegylated and pegylated forms of recombinant human alpha interferon 2a for suppression of dengue virus viremia in rhesus monkeys.},
  author={Chuanpis Ajariyakhajorn and Mammen P. Mammen and Tim P Endy and Montip Gettayacamin and Ananda N Nisalak and Suchitra Nimmannitya and Daniel H. Libraty},
  journal={Antimicrobial agents and chemotherapy},
  year={2005},
  volume={49 11},
  pages={4508-14}
}
Dengue fever and dengue hemorrhagic fever are caused by infection with any one of the four dengue viruses (DVs) and are significant public health burdens throughout the tropics. Higher viremia levels are associated with greater dengue disease severity. A therapeutic intervention to suppress viremia early in DV infection could potentially ameliorate severe disease. Recombinant alpha interferon 2a (rIFN-alpha-2a, Roferon-A) suppressed DV replication in human peripheral blood mononuclear cells in… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 19 extracted citations

Advances in the understanding, management, and prevention of dengue.

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology • 2015

Similar Papers

Loading similar papers…